Consider the Benefits of New Meds to Prevent Chemo-Induced Nausea and Vomiting
March 2018
You'll see more players join the crowded field of neurokinin-1 antagonists for chemotherapy-induced nausea and vomiting (CINV).
IV aprepitant (Cinvanti, sin-VAHN-tee) and IV rolapitant (Varubi, vuh-ROO-bee) will join IV fosaprepitant (Emend). There are also 3 ORAL meds...aprepitant (Emend, etc), rolapitant (Varubi), and netupitant combined with the 5-HT3 antagonist palonosetron (Akynzeo).
Expect neurokinin-1 antagonists to be included in HIGHLY and some MODERATELY emetogenic chemotherapy protocols to prevent CINV...in addition to a 5-HT3 antagonist (ondansetron, etc), dexamethasone, and possibly olanzapine (Zyprexa, etc).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote